Abstract
Objective: To investigate the molecular phenotype of the AIDS-onset delaying polymorphism in CXCL12β 3UTR (rs1801157). Methods: The 3UTRs of the CXCL12β isoform containing the A or G polymorphic variants were cloned downstream of the Luciferase gene under the control of the CXCL12 promoter. The plasmids were transfected in U373 and LC5 cells and the polymorphism phenotype was evaluated in terms of Luciferase activity and mRNA stability. Results: The 3A genotype compared to 3G leads to an increased luciferase activity in unstimulated and PMA+Ionomycin treated cells both in astrocytes (p= 0,0002, p = 0,02) and fibroblasts (p = 0,002, p = 0,03). The mRNA containing the 3A variant have two-fold longer half-life compared to the 3G variant (p = 6,99E-7). Conclusions: CXCL12β 3A polymorphism, previously associated with resistance to AIDS progression and other diseases, leads to increased levels of CXCL12 mRNA, the results presented here demonstrate that this effect is a consequence of an enhanced mRNA stability. Our data contribute to characterize the CXCL12 as a potential pharmacological target in AIDS, autoimmune diseases and cancer.
Keywords: CXCL12, mRNA stability, AIDS, rs1801157, UTR
Current HIV Research
Title: Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Volume: 7 Issue: 4
Author(s): Carelia Garcia-Moruja, Patricia Rueda, Carmen Torres, Jose Alcami, Francisco Luque and Antonio Caruz
Affiliation:
Keywords: CXCL12, mRNA stability, AIDS, rs1801157, UTR
Abstract: Objective: To investigate the molecular phenotype of the AIDS-onset delaying polymorphism in CXCL12β 3UTR (rs1801157). Methods: The 3UTRs of the CXCL12β isoform containing the A or G polymorphic variants were cloned downstream of the Luciferase gene under the control of the CXCL12 promoter. The plasmids were transfected in U373 and LC5 cells and the polymorphism phenotype was evaluated in terms of Luciferase activity and mRNA stability. Results: The 3A genotype compared to 3G leads to an increased luciferase activity in unstimulated and PMA+Ionomycin treated cells both in astrocytes (p= 0,0002, p = 0,02) and fibroblasts (p = 0,002, p = 0,03). The mRNA containing the 3A variant have two-fold longer half-life compared to the 3G variant (p = 6,99E-7). Conclusions: CXCL12β 3A polymorphism, previously associated with resistance to AIDS progression and other diseases, leads to increased levels of CXCL12 mRNA, the results presented here demonstrate that this effect is a consequence of an enhanced mRNA stability. Our data contribute to characterize the CXCL12 as a potential pharmacological target in AIDS, autoimmune diseases and cancer.
Export Options
About this article
Cite this article as:
Garcia-Moruja Carelia, Rueda Patricia, Torres Carmen, Alcami Jose, Luque Francisco and Caruz Antonio, Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression, Current HIV Research 2009; 7 (4) . https://dx.doi.org/10.2174/157016209788680543
DOI https://dx.doi.org/10.2174/157016209788680543 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Microchimerism in Health and Disease
Current Molecular Medicine Identification of Moesin as a Novel Autoantigen in Patients with Sjögren’s Syndrome
Protein & Peptide Letters Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease
Reviews on Recent Clinical Trials Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Current Medicinal Chemistry Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Update on the Use of Biologics in Lupus
Current Pharmaceutical Biotechnology Autoimmune Lymphoproliferative Syndrome (ALPS)
Current Pharmaceutical Design Chemokines as Drug Targets in Type 1 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Oral Contraceptives and Autoimmune Diseases
Current Women`s Health Reviews Roles of Glycans and Glycopeptides in Immune System and Immune-Related Diseases
Current Medicinal Chemistry Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry Potential Use of Drugs that Target Neural-Immune Pathways in the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy α-Galactosylceramide: Potential Immunomodulatory Activity and Future Application [General Articles]
Current Medicinal Chemistry NF-κB-IKKβ Pathway as a Target for Drug Development: Realities, Challenges and Perspectives
Current Drug Targets Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Medical and Societal Impact
Current Immunology Reviews (Discontinued) Pattern Recognition Receptors and Control of Innate Immunity: Role of Nucleic Acids
Current Pharmaceutical Biotechnology An Update on Autoinflammatory Diseases
Current Medicinal Chemistry